This week, a Vancouver-based mental health care company called Numinus got approval from Health Canada to conduct another round of MDMA clinical studies this year. Numinus has been at the forefront of emerging treatment options for mental health issues, including ketamine, MDMA, and psilocybin (magic mushrooms). Here’s the latest update.
To help with the new studies, Numinus has partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS), which is more or less the authority on psychedelic-related treatments right now. Together, they’ll be looking at the effects of MDMA treatments on those suffering from PTSD.
— Numinus Wellness (@NuminusWellness) July 12, 2021
While it won’t be the first time MDMA has been used in clinical studies, it does have an interesting note. This go-around, patients will not be required to stay on-site after their experience. Which, by the way, takes place in a ‘study room’ filled with music, plants, and other calming touches.
This latest study is set to have around 20 participants and should get off the ground later this year. We’re not going to lie, we don’t want people randomly trying to sneak into it on our account. If you, or someone you know, fits the legitimate requirements to participate, then you can check out more info right here.